Resources
8 Results (showing 1 - 8)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Rural Community Opioid Response Program (RCORP) grantees discussed their efforts and initiatives working with criminal justice and corrections agencies to engage individuals who are incarcerated.
Posted 6/7/2022 (updated 3/27/2024)
The presentation outlined how the Law Enforcement Assisted Diversion/Let Everyone Advance with Dignity (LEADD) pre-arrest diversion initiative operates. It covered how public health partners can engage with law enforcement to bring about a true collaborative approach to public safety. It further discussed how the LEAD model is rooted in harm reduction.
Posted 6/7/2022 (updated 3/27/2024)
These presentations highlighted the efforts of two MAT Expansion grantees to collaborate with partners, including local community corrections entities.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.